Semaphorin 7A (Sema7A), a neural guidance cue, was recently identified to regulate atherosclerosis in mice. However, the clinical relevance of Sema7A with atherosclerotic diseases remains unknown. The aim of this study was to investigate the association between serum Sema7A and the risk of acute atherothrombotic stroke (AAS).
| INTRODUC TI ON
Stroke is one of the leading causes of mortality and disability worldwide. Acute atherothrombotic stroke (AAS), the most common subtype, is a result of the atherosclerosis of cerebral arteries accounting for an overwhelming majority of deaths in China. 1, 2 The proatherogenic milieu consists of dysfunctional endothelium, activated leucocytes, platelets and inflammatory factors that facilitate atheroprogression and cardiovascular events. 3, 4 These molecules, reflecting systemic or focal inflammation, have shed light on the risk stratification of AAS. 5, 6 To date, emerging evidence suggests the roles of semaphorins, a protein family primarily detected on immunocyte membranes and signalling through plexins or integrins to exert versatile functions, 7 underlying atherosclerotic diseases since their initial demonstration as axonal guidance cues. [8] [9] [10] Among this family, semaphorin 7A (Sema7A) is a membrane protein encoded by SEMA7A gene on human chromosome 15 (25 kb) or mouse chromosome 9B (22 kb) and shows an important role in immune response, neural development, bone homeostasis, cancer and inflammation. [11] [12] [13] [14] Up-regulation of Sema7A expression has been associated with various inflammatory diseases, including interstitial lung disease, 15 multiple sclerosis (MS), 16 rheumatoid arthritis 17 and airway hypersensitivity.
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Recently, we demonstrated a causal role of Sema7A in experimental atherosclerosis via eliciting endothelial dysfunction and vascular inflammation, 19 whereas the clinical relevance of Sema7A in atherosclerotic disease remains to be elucidated. Therefore, we conducted this case-control study to investigate the association of serum Sema7A with AAS.
| MATERIAL S AND ME THODS

| Study population
We randomly selected 105 cases from a large cohort of patients with AAS from CATIS (China Antihypertensive Trial in Acute Ischemic Stroke). 20 In CATIS, patients with a systolic BP ≥220 mm Hg or diastolic BP ≥120 mm Hg, severe heart failure, acute myocardial infarction or unstable angina, atrial fibrillation, aortic dissection, cerebrovascular stenosis or resistant hypertension; those in a deep coma and those treated with intravenous thrombolytic therapy were excluded. The randomization process was conducted as follows: There were a total of 3170 patients with atherothrombotic stroke and with serum samples in CATIS. Among all these atherothrombotic stroke patients, we selected 105 patients as cases by means of simple random sampling method.
Controls free of stroke from a cross-sectional study in China were matched to the cases by 1:1 based on age (birth at the same year) and sex by SAS software. 
| Statistical analysis
Continuous variables with normal and skewed distribution were presented as means with standard deviation (SD) and medians with interquartile ranges (IQRs) respectively. Means and medians in variables between the two groups were compared using the paired Student's t test or Wilcoxon rank-sum test. Comparisons of percentages for categorical variables between the two groups were performed using the χ 2 test. Differences in Sema7A levels were evaluated between AAS cases and controls. Median Sema7A level (3.20 ng/mL) was served as cut-off and the study population was divided into low Sema7A (<3.20 ng/mL) and high Sema7A (≥3.20 ng/mL) groups.
Both univariate and multivariate logistic regression analyses were
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conducted to calculate the odds ratios (ORs) and 95% confidence intervals (95% CIs) of AAS associated with high Sema7A levels. In multivariate logistic analyses, adjustment variables included hypertension, BMI, current smoking, alcohol consumption, FBG, total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C). In addition, we assessed the improvement value of Sema7A for prediction of AAS risk by computing the area under receiver operating characteristic curves (AUC) and compared the model including Sema7A and other conventional risk factors to a model including only other conventional risk factors. 24 The association between serum Sema7A and high-sensitivity C-reactive protein (hsCRP) was evaluated using linear correlation and regression. A two-tailed P < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS software (version 22.0, IBM, Armonk, NY, USA) and MedCalc (version 15, MedCalc Software, Ostend, Belgium).
| RE SULTS
A total of 105 AAS patients and 105 age-and sex-matched controls were included in the analyses. As shown in Figure 1A ). After being divided by the median concentration of Sema7A (3.20 ng/mL), the proportion of cases was significantly higher in subjects with high Sema7A levels than that in those with low Sema7A levels (73.3% vs 26.7%, P < 0.001) ( Figure 1B ). Further analyses in 98 AAS patients showed no significant association between serum Sema7A and hsCRP levels (Pearson Correlation: −0.119, R 2 = 0.014, P = 0.245) ( Figure S1 ).
After controlling for conventional cardiovascular disease (CVD) risk factors including hypertension, BMI, FBG, TC, TG, HDL-C, LDL-C, current smoking and alcohol consumption, the multivariate-adjusted OR (95% CI) of AAS for high Sema7A levels was 6.40 (2.88-14.25) (P < 0.001), compared with low Sema7A. Additionally, each 1-SD increase of Sema7A was associated with a three times higher odds of AAS (adjusted OR = 3.42, 95% CI: 1.84-6.35; P < 0.001) ( Table 2 ).
As displayed in Figure 2 , the AUC for the model containing in atherosclerotic diseases, we selected AAS patients and a control population strictly matched for age and sex to investigate the clinical relevance of Sema7A. Before the current study, most of the human studies on Sema7A involved only a very small study population and lacked an appropriate control group. Moreover, previous studies used only simple statistical tests to explore the association between Sema7A and diseases without controlling for potential confounders. 15, 17, 25, 27 In contrast, the stringent criteria for selecting cases and controls in our study ensure comparability between AAS and control groups and minimize the interference from potential confounders. We further adjusted for some potential confounders in multivariate logistic analyses. We demonstrated an important result that elevated Sema7A was highly associated with AAS, which provided strong support to our previous findings in animal models of atherosclerosis.
| D ISCUSS I ON
The mechanisms underlying the observed association of serum Sema7A with AAS have been proposed in our previous study 19 Considering potential limitations of this study, our results should be interpreted cautiously. The current study is a case-control study with a relatively small study population, and with the nature of the cross section for the association of Sema7A with AAS because measurements of Sema7A were only obtained after AAS onset.
Therefore, the association of elevated Sema7A with AAS needs to be validated in future prospective studies. This case-control study aimed to investigate the association between Sema7A and AAS, while the association between other inflammatory factors and AAS was not evaluated, thus we were not able to compare the Sema7A level with other inflammation biomarkers in the whole study population and control their effects in the analyses. Since plasma Sema7A
was not measured in this study, we were not able to compare the levels of Sema7A between serum and plasma. Finally, our study was conducted only in Chinese Han population, thus may limit the generalization of the findings to other ethnic groups.
In summary, our results demonstrated that increased serum 
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